(D'arrigo, 2019) The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.pdf
D’Arrigo, P. et al. Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules. Curr. Med. Chem. (2018). https://doi.org/0.2174/0929867325666181106114421, (Epub ahead of print).
Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290–5301 (2014).
Berghoff, A. S. et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro. Oncol. 17, 1064–1075 (2015).
Nduom, E. K. et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 18, 195–205 (2016).
Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005).
Chen, R. Q., Liu, F., Qiu, X. Y. & Chen, X. Q. The prognostic and therapeutic value of pd-l1 in glioma. Front. Pharmacol. 9, 1503 (2018).
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007).
Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635–3643 (2008).
Zheng, F. et al. PD-L1 promotes self-renewal and tumorigenicity of malignant melanoma initiating cells. Biomed. Res. Int. 2017, 1–8 (2017).
Qiu, X. Y. et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1754–1769 (2018).
Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84–88 (2007).
Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
Romano, S. et al. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients. Pigment Cell Melanoma Res. 28, 442–452 (2015).
D’Arrigo, P. et al. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget 8, 68291–68304 (2017).
Hsu, J. M., Li, C. W., Lai, Y. J. & Hung, M. C. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 78, 6349–6353 (2018).
Jiang, W. et al. FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia 10, 235–243 (2008).
Romano, S. et al. The emerging role of large immunophilin FK506 binding protein 51 in cancer. Curr. Med. Chem. 18, 5424–5429 (2011).
Romano, S., D’Angelillo, A., Staibano, S., Ilardi, G. & Romano, M. F. FK506-binding protein 51 is a possible novel tumoral marker. Cell Death Dis. 1, e55 (2010).
Kroonen, J. et al. Human glioblastoma-initiating cells invade specifically the subventricular zones and olfactory bulbs of mice after striatal injection. Int. J. Cancer 129, 574–585 (2011).
Goffart, N. et al. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling. Neuro Oncol. 17, 81–94 (2015).
Wang, Y. & Wang, L. miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1. Biotechno. Lett. 39, 1485–1492 (2017).
Gaali, S. et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat. Chem. Biol. 11, 33–37 (2015).
Giordano, A. et al. Tirofiban counteracts endothelial cell apoptosis through the VEGF/VEGFR2/pAkt axis. Vasc. Pharmacol. 80, 67–74 (2016).
Romano, S. et al. Role of FK506 binding protein 51 [FKBP51] in the control of apoptosis of irradiated melanoma cells. Cell Death Differ. 17, 145–157 (2010).
Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184, 39–51 (1995).
Lin, D. et al. Tenomodulin is essential for prevention of adipocyte accumulation and fibrovascular scar formation during early tendon healing. Cell Death Dis. 8, e3116 (2017).
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).
Kim, W. et al. Real-time imaging of glioblastoma using bioluminescence in a U-87 MG xenograft model mouse. J. Korean Soc. Appl. Biol. Chem. 58, 243–248 (2015).
